Reports

Drug name	NICE TAs	Comments
Ocrelizumab	TA533 - Ocrelizumab for treating relapsing-remitting multiple sclerosis
Ocriplasmin (Jetrea®) injection	TA297 - Ocriplasmin for treating vitreomacular traction	For hospital use only
Ofatumumab	TA344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia	For hospital use only
Ofatumumab (Kesimpta®)	TA699 - Ofatumumab for treating relapsing multiple sclerosis
Olaparib (Lynparza®)	TA381 - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
Olaratumab	TA465 - Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma	For hospital use only
Omalizumab	TA339 - Omalizumab for previously treated chronic spontaneous urticaria TA278 - Omalizumab for treating severe persistent allergic asthma	Hospital only
Omalizumab#13.5	TA339 - Omalizumab for previously treated chronic spontaneous urticaria
Osimertinib	TA416 - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
Oxaliplatin injection	TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer TA33 - The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports